Sarcopenia is diagnosed by measuring three things: how much muscle you have, how strong it is, and how well you move. That part is settled.
What isn’t settled is where the lines fall. And when one expert group redrew those lines in 2019, the share of men diagnosed in one dataset dropped from 31.9% to 12.0% — same people, same measurements, different definition.
That’s worth understanding before you read any number about muscle loss.
The three components
Every major definition rests on the same three measurements.
Muscle mass — how much skeletal muscle you carry, usually appendicular (arms and legs) and adjusted for height or body size.
Muscle strength — almost always grip strength, measured with a dynamometer. Grip correlates moderately with strength elsewhere in the body, which is why one squeeze stands in for the whole[1].
Physical performance — gait speed over a short distance, or a chair stand test.
Where the groups diverge is in how these are weighted, and where each cutoff sits.
Strength moved to the front
The 2019 European revision made a structural change worth knowing.
EWGSOP2 puts muscle strength at the front of the algorithm, assessed by grip strength or a chair stand test[4]. Muscle mass is used to *confirm* the diagnosis rather than trigger it[4].
The Asian group made a parallel move. AWGS 2019 also recommends grip strength or chair stand as the first step, though it classifies the chair stand as physical performance rather than strength[4].
Both now stage the condition the same way: no sarcopenia, probable sarcopenia, confirmed sarcopenia, severe sarcopenia[4].
The reasoning is straightforward. Strength predicts adverse outcomes better than mass does, and it’s far easier to measure — no body composition equipment required.
When the definition changed, prevalence collapsed
Here’s the finding that reframed this topic for me.
Researchers applied both the 2010 and 2019 European definitions to the same eight cohorts — 2,256 participants, median cohort age 71.7 to 83.3 years[2].
- Men: 31.9% under EWGSOP, 12.0% under EWGSOP2
- Women: 4.9% under EWGSOP, 6.1% under EWGSOP2
Nothing about the participants changed. The grip strength thresholds did: from 30 kg to 27 kg for men, and from 20 kg to 16 kg for women[2]. Lower thresholds mean fewer people fall below them.
Two things stand out. The male figure fell by roughly two-thirds. And the two sexes moved in opposite directions — down for men, slightly up for women.
If you read that a given percentage of older adults has sarcopenia, the first question is which definition produced it.
Two regions, two sets of numbers
Europe and Asia use different thresholds, by design.
| Group | Men | Women |
| EWGSOP2 (Europe, 2019) | < 27 kg | < 16 kg |
| AWGS 2019 (Asia) | < 28 kg | < 18 kg |
[Table 1] Grip strength cutoffs by consensus group · Source: Based on EWGSOP2 and AWGS 2019 standards[1][4]
The Asian thresholds are higher, which makes them more inclusive — more people fall below the line.
You can see the effect directly. A study comparing UK and Japanese cohorts found low grip strength in 5.4% of Japanese versus 2.4% of UK participants under EWGSOP2, and 9.0% versus 3.7% under AWGS 2019[3].
Both criteria found the Japanese cohort had more low grip strength. But the Asian criteria roughly doubled the figure in both populations.
Reassuringly, the same study found that the correlates of muscle strength were similar in both cohorts — older age, shorter height, more comorbidity[3]. The underlying biology looks alike. The measuring stick differs.
Where cutoffs come from
The thresholds aren’t discovered. They’re chosen.
The usual method is to take a young reference population, calculate the mean, and set the cutoff some number of standard deviations below it. How many standard deviations is a judgement call.
The German National Cohort demonstrated how much that judgement matters. Using data from over 200,000 adults, applying −2, −2.5, and −3 standard deviations produced low grip strength prevalence of 43.0%, 20.7%, and 11.1% respectively[5].
A fourfold spread, from the same data, purely from where the line is drawn.
That study also derived its own cutoffs from German data — < 29 kg for men and < 18 kg for women — noticeably higher than EWGSOP2’s 27 and 16[5].
A bit more detail — for readers interested in whether official cutoffs are optimal. A study of 6,182 adults aged 60+ from the English Longitudinal Study of Ageing tested which grip thresholds best identified mortality risk. The best-performing cutoffs were < 36 kg for men and < 23 kg for women[6] — well above every official threshold in use. Sensitivity was 58.6% for men and 68.9% for women, with areas under the curve of 0.66 and 0.64[6]. Modest accuracy, but the direction is notable: thresholds tuned for predicting death sit considerably higher than thresholds set for diagnosis.
What this means when you read about muscle loss
A few habits that follow.
Check which criteria produced a prevalence figure. A study reporting 30% and one reporting 12% may be describing identical populations.
Don’t compare your grip number to a threshold from another region. 27 kg and 28 kg sound interchangeable; they’re separate consensus decisions.
Treat “probable sarcopenia” as what it says. Under both current definitions, low strength alone gets you that label — muscle mass is still needed to confirm.
Remember the cutoff is a line, not a cliff. Grip strength relates to mortality in a nearly linear fashion[5]. Nothing changes physiologically at 27 kg.
If you’re in Korea
Two practical notes.
Korea sits within the AWGS 2019 framework, so the thresholds you’d be assessed against here are 28 kg for men and 18 kg for women — higher than European ones. If you were assessed in Europe and are now in Korea, or the reverse, the same grip reading could land on different sides of the line.
Body composition analysers are widely available here, in gyms and health centres as well as clinics. Those give you the muscle mass component, but mass alone doesn’t establish sarcopenia under either definition — strength or performance has to be low as well. A body composition printout is a starting point, not an answer.
Closing
The three components are stable. Muscle mass, strength, physical performance — every serious definition uses them.
What I hadn’t appreciated was how much rests on the thresholds, and how recently they moved. A definitional revision cut male prevalence in one dataset from 31.9% to 12.0%. A choice between −2 and −3 standard deviations swung another figure from 43% to 11%.
That doesn’t make the diagnosis arbitrary. It does mean a single number — yours or a study’s — carries less standalone meaning than it appears to. What the criteria are consistently good at is flagging people worth assessing further, and that remains the point of measuring at all.
At a Glance
- Three components: muscle mass, muscle strength, physical performance
- EWGSOP2 (2019) and AWGS 2019 both put strength first; mass now confirms rather than triggers
- Staging: no sarcopenia → probable → confirmed → severe
- Applying EWGSOP vs EWGSOP2 to the same cohorts: male prevalence 9% → 12.0%; female 4.9% → 6.1%
- Grip cutoffs: EWGSOP2 27 kg / 16 kg AWGS 2019 28 kg / 18 kg — Asian thresholds are higher
- UK vs Japan low grip strength: 2.4% vs 5.4% (EWGSOP2), 3.7% vs 9.0% (AWGS)
- In 200,000+ German adults, choosing −2, −2.5 or −3 SD gave prevalence of 0%, 20.7%, 11.1%
- Grip strength relates to mortality nearly linearly — the cutoff is a line, not a cliff
※ This article explains how diagnostic criteria are constructed and is for general information only. It does not replace medical diagnosis, interpretation or treatment. A body composition reading or grip measurement does not by itself establish a diagnosis. If you are concerned about muscle loss, strength or mobility, please consult a clinician rather than interpreting a number on your own.
References
- “Sarcopenia: EWGSOP2 and AWGS grip strength cut-off values” (comparison of consensus thresholds), Ibom Medical Journal, https://www.ibommedicaljournal.org/index.php/imjhome/article/download/604/1302?inline=1
- “Impact of using the updated EWGSOP2 definition in diagnosing sarcopenia: A clinical perspective”, Clinical Nutrition ESPEN, https://www.sciencedirect.com/science/article/pii/S0167494320301199
- “Do lifestyle, anthropometric and demographic factors associated with muscle strength differ in a UK and Japanese cohort? An exploratory analysis”, PMC, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10721682/
- “Handgrip strength rather than chair stand test should be used to diagnose sarcopenia in geriatric rehabilitation inpatients (RESORT)”, Age and Ageing 2022;51(11), https://academic.oup.com/ageing/article/51/11/afac242/6834150
- “Grip strength values and cut-off points based on over 200,000 adults of the German National Cohort — a comparison to the EWGSOP2 cut-off points”, Age and Ageing 2023;52(1), https://academic.oup.com/ageing/article/52/1/afac324/6998045
- “EWGSOP1 and EWGSOP2 criteria or slowness: which is the best predictor of mortality risk in older adults?”, Age and Ageing 2022;51(7), https://pubmed.ncbi.nlm.nih.gov/35906934/